Concepedia

Kimberly Feigin

KF

Statistics

Publications

11

Citations

1K

H-Index

11

Active since

2005

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Cornell University

Dana-Farber Cancer Institute

Kimberly Feigin is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and pharmacology.

ORCID

Publications per year

2005–2023

11

Publications

11

Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

Ayca Gucalp, Sara M. Tolaney, Steven J. Isakoff et al. · Clinical Cancer Research · 2013 · 740 citations

, , +16

Phase I Study of a Novel Capecitabine Schedule Based on the Norton-Simon Mathematical Model in Patients With Metastatic Breast Cancer

Tiffany A. Traina, Maria Theodoulou, Kimberly Feigin et al. · Journal of Clinical Oncology · 2008 · 72 citations

, , +17

Targeting the androgen receptor (AR) in women with AR+ ER-/PR- metastatic breast cancer (MBC).

Ayca Gucalp, Sara M. Tolaney, Steven J. Isakoff et al. · Journal of Clinical Oncology · 2012 · 31 citations

, , +17

Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.

Ayca Gucalp, Leigh Ann Boyle, Tina Alano et al. · Journal of Clinical Oncology · 2020 · 29 citations

, , +17

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer

Devika Gajria, Joseph Gonzalez, Kimberly Feigin et al. · Breast Cancer Research and Treatment · 2011 · 28 citations

, , +16

1–5 of 11